Logo Prima Biomed

Welcome to the Newsroom

19 January 2015

Prima BioMed appoints Global Head of Investor Relations


SYDNEY,  AUSTRALIA  -  Prima  BioMed  Ltd  (ASX:  PRR;  NASDAQ:  PBMD) (“Prima”)  today announced the appointment of Stuart Roberts as Global Head of Investor Relations.  Mr Roberts is an experienced investment professional, with expertise in the healthcare and biotechnology sectors, and has been involved in Australian equity research for 16 years. He builds  his  reputation  as  one  of  Australia’s  leading  sell-side  biotech  analysts  and  has  been working with Baillieu Holst and Bell Potter before joining Prima.   Prima CEO, Marc Voigt said the appointment followed the recent acquisition of French biotechnology company, Immutep, which has the potential to deliver significant benefits for Prima.   “We now have a much more compelling investment story and Stuart is an ideal fit for our company as he has a proven track record in making complex, technology-based investment ideas easy to understand. As well he is passionate about Life Sciences and he has a deep understanding of the biotechnology sector,” Mr Voigt said.